NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
This strategic investment strengthens Cohance's integrated oligonucleotide platform
The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
Subscribe To Our Newsletter & Stay Updated
